NovaMedica appoints Rustam Iksanov as R&D Vice President

11 August 2017

Moscow, August 11, 2017 – Rustam Iksanov, who used to hold one of the managerial positions in Valenta Pharma, has been appointed as R&D Vice President of pharmaceutical company NovaMedica.

“The level of tasks, that we set  for our R&D division, is a real challenge within the current situation in the Russian pharmaceutical market. I am confident that Rustam Iksanov, who possesses great experience in development of commercially successful products in different companies, will cope with these tasks perfectly”, noted Alexander Kuzin, CEO of NovaMedica.

“I am glad that I have the opportunity to join NovaMedica team which within a very short time has managed to gain prominent results in the market. I am inspired by the task to structure work under R&D projects and creation of new drug products which will be basis of the product portfolio of our company”, said Rustam Iksanov.

Rustam Iksanov has been working in the Russian pharmaceutical market for more than 17 years. Before joining NovaMedica he took the position of M&A Director in Valenta Pharm where he managed  the business development of Gastroenterology division. He developed strategic scenarios of product portfolio development, managed pipeline projects and was responsible for search of potential targets for acquisition (products, developments, companies), preparation and implementation of deals.

Earlier Rustam was Vice President for Strategic Development in Akrikhin (Polpharma), he also hold managerial positions in the field of development products and product portfolio in Izvariono Pharma (Ferring Pharmaceuticals) and Nizhpharm (Stada). Before that he held classes at the Nizhny Novgorod State Medical Academy and worked as a physician.  

Rustam graduated with honors from the Nizhny Novgorod State Medical Academy. In addition, he undertook special programs devoted to commercialization of technologies in the Russian Presidential Academy of National Economy and to pharmaceutical management and economics in the Peoples’ Friendship University of Russia.

Rustam is co-developer of more than 10 inventions in the field of pharmacy, which are protected by patents of the Russian Federation. 

NovaMedica is a modern Russian pharmaceutical company founded in 2012 by Domain Associates LLC, leading U.S. venture capital firm, and RUSNANO, JSC (RUSNANO controls 50% of NovaMedica shares through the venture fund RusnanoMedInvest). NovaMedica's strategy is aimed at search, registration and localization in Russia of intellectual property rights for innovative pharmaceuticals products and technologies, as well as at development and implementation of own R&D projects.

NovaMedica owns intellectual property rights within Russia and the CIS on innovative developments from the portfolio of the RusnanoMedInvest venture fund. Today NovaMedica’s pipeline already has 36 IP for preparations for antiviral and anti-inflammatory therapy, treatment of ophthalmic diseases and epilepsy, innovative technologies for detection of oncological and infectious diseases. Also NovaMedica is working on creation of a number of its own products. R&D department of the company plans to develop about 15 innovative drugs until 2022. These are drugs for treatment of diseases in the field of gastroenterology, pain management, neurology, ophthalmology and rheumatology.

In April 2017, NovaMedica opened the Technological Center with a complex of R&D laboratories and pilot production in Technopolis “Moscow”. The Technological Center has the latest technological capabilities previously unavailable in the Russian pharmaceutical industry. The company also has a developed infrastructure for promoting and selling pharmaceutical products.

Read more about us on, follow us on Facebook and LinkedIn

Contacts for media: Tatiana Albaut  , +79175451241

Previous publication Next publication

Media Center

  • 20 March 2018

    Russia establishes its National Quality Infrastructure Council

    On March 14, Denis Manturov, the Russian Minister of Industry and Trade, chaired a meeting of the State Commission on Counteraction to Illegal Circulation of Industrial Products. The Minister said that, ensuring the “market purity” would require, in addition to providing more preferences for entrepreneurs operating strictly within the legal field, to guarantee to potential consumers that they purchase genuine rather than counterfeit and falsified products.

  • 20 March 2018

    Researchers in aging tie genes to brain degeneration

    As brain cells age, they lose their ability to perform basic functions, often leading to dementia and other neurodegenerative disorders. But what’s behind this decline, and can it be stopped? Two new studies out this week uncover links between genes and brain-cell functioning that could provide new targets for therapies aimed at neurodegenerative diseases.

  • 19 March 2018

    China established a new drug regulator

    After about five years as a standalone agency, the China Food and Drug Administration (CFDA) will merge into a gigantic national market supervision administration, with drug regulation as a new, second-tier bureau underneath.

  • 19 March 2018

    Project of EAEU unified goods traceability system was presented to the public

    The unified goods traceability system in the Eurasian Economic Union (EAEU) will provide consumers with access to reliable information about products, allow businesses to reduce their transaction costs, let member states to monitor the payment of taxes, minimize smuggling, and protect consumers.

Read more